Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Ocaña A, Chacón JI, Calvo L, Antón A, Mansutti M, Albanell J, Martínez MT, Lahuerta A, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chan A, Morales S, Herranz J, Tusquets I, Chiesa M, Caballero R, Valagussa P, Bianchini G, Alba E, Gianni L. Ocaña A, et al. Among authors: morales s. Front Oncol. 2022 Feb 11;11:827625. doi: 10.3389/fonc.2021.827625. eCollection 2021. Front Oncol. 2022. PMID: 35223459 Free PMC article.
Interferon and disseminated Langerhans cell histiocytosis.
Bellmunt J, Albanell J, Salud A, Español T, Morales S, Solé-Calvo LA. Bellmunt J, et al. Among authors: morales s. Med Pediatr Oncol. 1992;20(4):336-7. doi: 10.1002/mpo.2950200413. Med Pediatr Oncol. 1992. PMID: 1608357 No abstract available.
Adjuvant docetaxel for high-risk, node-negative breast cancer.
Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodríguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A; GEICAM 9805 Investigators. Martín M, et al. N Engl J Med. 2010 Dec 2;363(23):2200-10. doi: 10.1056/NEJMoa0910320. N Engl J Med. 2010. PMID: 21121833 Free article. Clinical Trial.
Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.
Sánchez-Rovira P, Seguí MA, Llombart A, Aranda E, Antón A, Sánchez A, Lomas M, Jaén A, Fernández M, Porras I, Dalmau E, Morales S, de la Haba-Rodríguez J. Sánchez-Rovira P, et al. Among authors: morales s. Clin Transl Oncol. 2013 Oct;15(10):810-7. doi: 10.1007/s12094-013-1006-4. Epub 2013 Feb 9. Clin Transl Oncol. 2013. PMID: 23397155 Free PMC article. Clinical Trial.
Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
Martín M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JÁ, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba-Rodriguez JR. Martín M, et al. Among authors: morales s. J Clin Oncol. 2015 Mar 20;33(9):1045-52. doi: 10.1200/JCO.2014.57.2388. Epub 2015 Feb 17. J Clin Oncol. 2015. PMID: 25691671 Clinical Trial.
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.
Martín M, González-Rivera M, Morales S, de la Haba-Rodriguez J, González-Cortijo L, Manso L, Albanell J, González-Martín A, González S, Arcusa A, de la Cruz-Merino L, Rojo F, Vidal M, Galván P, Aguirre E, Morales C, Ferree S, Pompilio K, Casas M, Caballero R, Goicoechea U, Carrasco E, Michalopoulos S, Hornberger J, Prat A. Martín M, et al. Among authors: morales s, morales c. Curr Med Res Opin. 2015 Jun;31(6):1129-37. doi: 10.1185/03007995.2015.1037730. Epub 2015 Apr 23. Curr Med Res Opin. 2015. PMID: 25851308
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J. Llombart-Cussac A, et al. Among authors: morales s. Breast Cancer Res Treat. 2015 Nov;154(2):351-7. doi: 10.1007/s10549-015-3616-8. Epub 2015 Nov 4. Breast Cancer Res Treat. 2015. PMID: 26536871 Free PMC article. Clinical Trial.
Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Llombart-Cussac A, Ramos M, Dalmau E, García-Saenz JA, González-Farré X, Murillo L, Calvo L, Morales S, Carañana V, González A, Fernández-Morales LA, Moreno F, Casas MI, Angulo Mdel M, Cámara MC, Garcia-Mace AI, Carrasco E, Jara-Sánchez C. Llombart-Cussac A, et al. Among authors: morales s. Eur J Cancer. 2016 May;58:122-9. doi: 10.1016/j.ejca.2016.01.015. Epub 2016 Mar 17. Eur J Cancer. 2016. PMID: 26994459 Clinical Trial.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A. Llombart-Cussac A, et al. Among authors: morales s. Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24. Lancet Oncol. 2017. PMID: 28238593 Clinical Trial.
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M, Galván P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Paré L, Alonso I, Albanell J, Vivancos A, González A, Matito J, González S, Fernandez P, Adamo B, Muñoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M. Fernandez-Martinez A, et al. Among authors: morales s. Oncotarget. 2017 Mar 28;8(13):21930-21937. doi: 10.18632/oncotarget.15748. Oncotarget. 2017. PMID: 28423537 Free PMC article.
648 results